---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-015329"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:25:06.609850+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition Corp. II completes $184M IPO and $5M private placement; trust funded

## Summary
- IPO of 18.4M Class A shares at $10.00 each included full exercise of 2.4M over-allotment shares.
- Private sale of 509,000 Class A shares to sponsor Helix Holdings LLC at $10.00/share, gross $5.09M.
- Net proceeds of $184M (including $5.52M deferred underwriting fee) deposited into trust account.
- Audited balance sheet at Feb 13, 2024: $184M in trust, $2.5M cash, $3.2M shareholders' deficit.
- SPAC focused on healthcare; must complete initial business combination within 24 months.

## SEC filing metadata
- accession: 0001213900-24-015329
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390024015329/0001213900-24-015329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390024015329/ea0200237-8k_helixacq2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-015329
- JSON: https://secwatch.observer/filing/0001213900-24-015329.json
- Plain text: https://secwatch.observer/filing/0001213900-24-015329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.